At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 249 enrolled

Drug / intervention

CNTO 1275drug

Likely dose

Not stated in record

Key inclusion· 2

✓Definite diagnosis of relapsing-remitting multiple sclerosis
✓Documented relapse activity: either ≥2 relapses within the 2 years before screening (but not in the prior month), OR ≥1 relapse within 6 months before screening (but not in the prior month)

Key exclusion· 4

✕Other CNS diseases (e.g., CNS lymphoma, systemic lupus erythematosus)
✕Significant bulbar involvement or other significant neurologic deficits from MS
✕Decubitus ulcer
✕Immunomodulatory therapies within 3 months of screening

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00207727

NCT00207727Phase 2Completed

A Phase II, Double-blind, Placebo-Controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40(CNTO1275) in Subjects With Relapsing-remitting Multiple Sclerosis

Centocor, Inc.·interventional·Posted Sep 21, 2005·Updated Apr 23, 2012

In Brief

A Phase 2 clinical trial evaluating CNTO 1275 for Multiple Sclerosis. Completed, enrolled 249 participants.

The purpose of the study is to evaluate the effectiveness and safety of CNTO 1275 in patients with Multiple Sclerosis

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

Countries--

CollaboratorsCentocor BV

Phase 2CompletedFinished

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJul 2004

First PostedSep 2005

Primary CompletionMar 2006

Study CompletionAug 2006

TodayJul 2026

First PostedSep 21, 2005

Enrollment StartJul 1, 2004

Primary CompletionMar 1, 2006

Study CompletionAug 1, 2006

TodayJul 2, 2026

Enrollment to primary: 1.7 yearsPosted 20.8 years ago

CNTO 1275drug